Anti-estrogenic treatment and HER2 inhibitors are used to treat hidradenocarcinoma, mucinous carcinoma, or apocrine adenocarcinoma, with variable outcomes [90,98,156]. This evidence concerns the gene ERBB2 and mucinous adenocarcinoma.